INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
SEC FORM 4/Open-market saleVerified dataRule 10b5-1 plan

Wang Xiaodong sold ONC

Director, Chair, Scientific Advisory Brd · BeOne Medicines Ltd. · American Depositary Shares

Side
SELL
Value
$2.31M
Shares
6,558
Price
$352.57
Executed
Oct 13, 2026
Disclosed
Oct 15, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Oct 13 executedOct 15, 2026 disclosed

ONC · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
24/ 100 · ROUTINE
Methodology →
  • Transaction type+6 / 20

    Open-market sale

  • Relative size+22 / 25

    $2.3M reported value · 83.9% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+1 / 15

    Routine: 18 prior trades recorded in this security

  • Frequency & clustering+5 / 15

    1 other actor traded the same direction within 14 days

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • Pre-arranged plan-10

    Executed under a Rule 10b5-1 trading plan

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · ONC

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    15
    WX
    Wang XiaodongDirector, Chair, Scientific Advisory Brd
    ONCBeOne Medicines Ltd.
    Open-market sale · 10b5-1 plan
    		SELL$1.03M
    2,841 sh
    		Oct 27, 2026Oct 29, 2026
    traded Oct 27, 2026
    		+2dSEC FORM 4

    Evidence

    4
    WX
    Wang XiaodongDirector, Chair, Scientific Advisory Brd
    ONCBeOne Medicines Ltd.
    Open-market sale · 10b5-1 plan
    		SELL$512K
    1,440 sh
    		Oct 27, 2026Oct 29, 2026
    traded Oct 27, 2026
    		+2dSEC FORM 4

    Evidence

    8
    WX
    Wang XiaodongDirector, Chair, Scientific Advisory Brd
    ONCBeOne Medicines Ltd.
    Open-market sale · 10b5-1 plan
    		SELL$603K
    1,681 sh
    		Oct 27, 2026Oct 29, 2026
    traded Oct 27, 2026
    		+2dSEC FORM 4

    Evidence

    15
    WX
    Wang XiaodongDirector, Chair, Scientific Advisory Brd
    ONCBeOne Medicines Ltd.
    Open-market sale · 10b5-1 plan
    		SELL$1.45M
    3,965 sh
    		Oct 27, 2026Oct 29, 2026
    traded Oct 27, 2026
    		+2dSEC FORM 4

    Evidence

    8
    WX
    Wang XiaodongDirector, Chair, Scientific Advisory Brd
    ONCBeOne Medicines Ltd.
    Open-market sale · 10b5-1 plan
    		SELL$845K
    2,331 sh
    		Oct 27, 2026Oct 29, 2026
    traded Oct 27, 2026
    		+2dSEC FORM 4

    Evidence

    15
    WX
    Wang XiaodongDirector, Chair, Scientific Advisory Brd
    ONCBeOne Medicines Ltd.
    Open-market sale · 10b5-1 plan
    		SELL$2.96M
    8,148 sh
    		Oct 27, 2026Oct 29, 2026
    traded Oct 27, 2026
    		+2dSEC FORM 4

    Evidence

    1
    WX
    Wang XiaodongDirector, Chair, Scientific Advisory Brd
    ONCBeOne Medicines Ltd.
    Open-market sale · 10b5-1 plan
    		SELL$115K
    320 sh
    		Oct 27, 2026Oct 29, 2026
    traded Oct 27, 2026
    		+2dSEC FORM 4

    Evidence

    4
    WX
    Wang XiaodongDirector, Chair, Scientific Advisory Brd
    ONCBeOne Medicines Ltd.
    Open-market sale · 10b5-1 plan
    		SELL$460K
    1,280 sh
    		Oct 27, 2026Oct 29, 2026
    traded Oct 27, 2026
    		+2dSEC FORM 4

    Evidence

    4
    WX
    Wang XiaodongDirector, Chair, Scientific Advisory Brd
    ONCBeOne Medicines Ltd.
    Open-market sale · 10b5-1 plan
    		SELL$313K
    880 sh
    		Oct 27, 2026Oct 29, 2026
    traded Oct 27, 2026
    		+2dSEC FORM 4

    Evidence

    19
    WX
    Wang XiaodongDirector, Chair, Scientific Advisory Brd
    ONCBeOne Medicines Ltd.
    Open-market sale · 10b5-1 plan
    		SELL$2.53M
    6,903 sh
    		Oct 27, 2026Oct 29, 2026
    traded Oct 27, 2026
    		+2dSEC FORM 4

    Evidence

    4
    WX
    Wang XiaodongDirector, Chair, Scientific Advisory Brd
    ONCBeOne Medicines Ltd.
    Open-market sale · 10b5-1 plan
    		SELL$443K
    1,239 sh
    		Oct 27, 2026Oct 29, 2026
    traded Oct 27, 2026
    		+2dSEC FORM 4

    Evidence

    0
    WX
    Wang XiaodongDirector, Chair, Scientific Advisory Brd
    ONCBeOne Medicines Ltd.
    Option exercise · 10b5-1 plan
    		M—
    403.4K sh
    		Oct 27, 2026Oct 29, 2026
    traded Oct 27, 2026
    		+2dSEC FORM 4

    Evidence

    1
    WX
    Wang XiaodongDirector, Chair, Scientific Advisory Brd
    ONCBeOne Medicines Ltd.
    Option exercise · 10b5-1 plan
    		M$1.14M
    31.0K sh
    		Oct 27, 2026Oct 29, 2026
    traded Oct 27, 2026
    		+2dSEC FORM 4

    Evidence

    1
    WX
    Wang XiaodongDirector, Chair, Scientific Advisory Brd
    ONCBeOne Medicines Ltd.
    Option exercise · 10b5-1 plan
    		M$1.14M
    31.0K sh
    		Oct 13, 2026Oct 15, 2026
    traded Oct 13, 2026
    		+2dSEC FORM 4

    Evidence

    20
    WX
    Wang XiaodongDirector, Chair, Scientific Advisory Brd
    ONCBeOne Medicines Ltd.
    Open-market sale · 10b5-1 plan
    		SELL$3.63M
    10.4K sh
    		Oct 13, 2026Oct 15, 2026
    traded Oct 13, 2026
    		+2dSEC FORM 4

    Evidence

    21
    WX
    Wang XiaodongDirector, Chair, Scientific Advisory Brd
    ONCBeOne Medicines Ltd.
    Open-market sale · 10b5-1 plan
    		SELL$445K
    1,260 sh
    		Oct 13, 2026Oct 15, 2026
    traded Oct 13, 2026
    		+2dSEC FORM 4

    Evidence

    4
    WX
    Wang XiaodongDirector, Chair, Scientific Advisory Brd
    ONCBeOne Medicines Ltd.
    Option exercise · 10b5-1 plan
    		M—
    403.4K sh
    		Oct 13, 2026Oct 15, 2026
    traded Oct 13, 2026
    		+2dSEC FORM 4

    Evidence

    20
    WX
    Wang XiaodongDirector, Chair, Scientific Advisory Brd
    ONCBeOne Medicines Ltd.
    Open-market sale · 10b5-1 plan
    		SELL$2.00M
    5,681 sh
    		Oct 13, 2026Oct 15, 2026
    traded Oct 13, 2026
    		+2dSEC FORM 4

    Evidence

    20
    WX
    Wang XiaodongDirector, Chair, Scientific Advisory Brd
    ONCBeOne Medicines Ltd.
    Open-market sale · 10b5-1 plan
    		SELL$2.51M
    7,167 sh
    		Oct 13, 2026Oct 15, 2026
    traded Oct 13, 2026
    		+2dSEC FORM 4

    Evidence

    21
    LH
    Lee Chan HenrySVP, General Counsel
    ONCBeOne Medicines Ltd.
    Open-market sale · 10b5-1 plan
    		SELL$418K
    1,115 sh
    		Sep 30, 2026Oct 2, 2026
    traded Sep 30, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001662982-26-000006
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Oct 13, 2026
    Published
    Oct 15, 2026
    Ingested by INSIDER
    Nov 5, 02:11 UTC
    Last re-read
    Nov 5, 02:11 UTC

    Extracted facts

    Filer
    Wang Xiaodong
    Role
    Director, Chair, Scientific Advisory Brd
    Transaction
    Open-market saleAs filed: “S”
    Asset
    BeOne Medicines Ltd.
    Ticker
    ONC
    Shares
    6,558
    Price per share
    $352.57
    Value
    $2,312,148
    Execution date (reported)
    Oct 13, 2026
    Owned after transaction
    1,260 shares
    Rule 10b5-1 plan
    Yes, as checked by the filer
    Days from execution to publication
    2

    Calculation

    Value = shares × reported price per share

    • Shares: 6,558
    • Price: $352.5691

    = $2,312,148

    What this establishes

    Wang Xiaodong filed this Form 4 reporting a open-market sale of ONC on Oct 13, 2026. It became public on Oct 15, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, Chair, Scientific Advisory Brd
    Wang Xiaodongcik:0001662982
    Issuer
    BeOne Medicines Ltd.cik:0001651308

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.